Research letter: The impact of elexacaftor/tezacaftor/ivacaftor on adherence to nebulized maintenance therapies in people with cystic fibrosis
- 16 May 2022
- journal article
- letter
- Published by Elsevier in Journal of Cystic Fibrosis
- Vol. 21 (6) , 1080-1081
Abstract
No abstract availableKeywords
Funding Information
- Cystic Fibrosis Canada (6554)
- Michael Smith Health Research BC (-2020-0493, 16414)
This publication has 5 references indexed in Scilit:
- Persistent recovery of pancreatic function in patients with cystic fibrosis after ivacaftorPediatric Pulmonology, 2020
- Elexacaftor–Tezacaftor–Ivacaftor for Cystic Fibrosis with a Single Phe508del AlleleNew England Journal of Medicine, 2019
- Efficacy and safety of the elexacaftor plus tezacaftor plus ivacaftor combination regimen in people with cystic fibrosis homozygous for the F508del mutation: a double-blind, randomised, phase 3 trialThe Lancet, 2019
- Pulmonary Medication Adherence and Health-care Use in Cystic FibrosisChest, 2014
- High treatment burden in adults with cystic fibrosis: Challenges to disease self-managementJournal of Cystic Fibrosis, 2009